1. Augenlich L, Wadler S, Gorner G, Richards C, Ryan L, Multani A, Pathak S, Benson A, Haller D, Heerdt B (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 1769–1775
2. Aulmann S, Bentz M, Sinn HP (2002) C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 74: 25–31
3. Berns E, Klijn J, Van Putten W, van Staveren I, Portengen H, Foekens J (1992) c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52: 1107–1113
4. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M (1999) Quantitation of MYC gene expression in sporadic breast tumors with a real-time transcription-PCR assay. Cancer Res 59: 2759–2765
5. Chana J, Cree I, Foss A, Hungerford J, Wilson G (1998a) The prognositc significance of c-myc oncogene expression in uveal melanoma. Melanoma Res 8: 139–144